Group A Streptococcus (GAS) or Streptococcus pyogenes is a Gram-positive organism commonly found in the throat and skin. Although colonization with GAS is mostly harmless,
the bacteria can cause a wide spectrum of diseases and inflammatory sequelae. GAS infections range from mild superficial infections such as pharyngitis “strep throat” to severe invasive
life-threatening diseases (iGAS) such as necrotizing fasciitis (NF) or “flesh eating disease”. GAS is also responsible for rheumatic heart disease (RHD) which is estimated to kill thousands
of people each year, mostly in developing regions.
This MarketVIEW product is a comprehensive opportunity assessment investigating the commercial potential of GAS vaccine indications for the Western developing world as well
as ROW/emerging markets. The product consists of an executive presentation detailing all relevant topics pertain to GAS vaccine commercialization including ideal target product profile,
clinical development issues and competitive environment. Also included is a detailed MS Excel value/volume demand forecast to 2030 for all relevant indications/regions. This product is a
ideal tool to aid early stage decision making in GAS vaccine development.
THIS PRODUCT IS A SUMMARY PRESENTATION + ONE MODEL
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW.
For UK orders VAT will be added at 20% (from January 2011)
Please review the TERMS and CONDITIONS of purchase.
